Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211085 | 1.00 | CTSK (0.41) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL21712199 | 0.91 | CTSK (0.48) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL31277239 | 0.91 | CTSK (0.48) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6122546 | 0.91 | CTSK (0.52) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6122539 | 0.91 | CTSK (0.52) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6122543 | 0.91 | CTSK (0.52) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL20211087 | 0.90 | CTSK (0.48) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL17009235 | 0.90 | CTSK (0.48) | CTSKHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6121766 | 0.87 | PLA2G2C (0.40) | CTSKHDAC1PPARGPPARA | |
| SCHEMBL20211111 | 0.85 | CTSK (0.43) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | 7 HILLS PHARMA INC. (US) | 2025-01-21 | — | — | US | claimed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | CTSK 1937/4885HDAC3 828/4885HDAC1 1093/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | CTSK 1100/4885HDAC3 835/4885HDAC1 281/4885 |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | CD47, CD274, ITGB1 | CTSK 2225/4885HDAC3 123/4885HDAC1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.